What Happened

Cadrenal Therapeutics presented Phase 2 results at ISTH Congress showing CAD-1005 reduced thrombotic events by >25% in HIT patients when combined with standard anticoagulants. The data came from the first randomized, placebo-controlled trial in HIT, presented in the conference's late-breakthrough session.

Who Is Affected

Hematologists, critical care specialists, and hospital formularies managing HIT patients. Current anticoagulants don't address the underlying platelet activation, leaving 30-50% thrombotic risk even with treatment.

Market Impact

• Creates first direct competitor to existing HIT anticoagulants (argatroban, bivalirudin)
• FDA Fast Track status suggests accelerated approval pathway
• Orphan Drug designation provides 7-year US market exclusivity if approved

What to Watch

Phase 3 trial design and partnership announcements. Cadrenal is a small-cap biotech (market cap ~$15M) likely seeking commercialization partners for this $300M+ potential HIT market.